<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04561752</url>
  </required_header>
  <id_info>
    <org_study_id>ZN-c5-006</org_study_id>
    <nct_id>NCT04561752</nct_id>
  </id_info>
  <brief_title>A Food Effect Study With ZN-c5 in Healthy Post-Menopausal Subjects</brief_title>
  <official_title>A Randomized, Open-Label, 2-Way Crossover, Single-Dose Food Effect Study of ZN-c5 in Healthy Adult Post-Menopausal Female Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zeno Alpha Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zeno Alpha Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, randomized, open-label, two-period, 2-way crossover food effect&#xD;
      study to determine the comparative bioavailability of ZN-c5 under fed and fasting conditions,&#xD;
      following single-dose administration of ZN-c5 capsules (150mg).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2, 2020</start_date>
  <completion_date type="Actual">December 16, 2020</completion_date>
  <primary_completion_date type="Actual">December 11, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>All participants will receive the same treatment but are randomized to one of two different treatment sequences in fed and fasted states.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC0-t</measure>
    <time_frame>Days 1-4</time_frame>
    <description>Area under the plasma concentration-time curve (AUC) from time zero to the last sampling time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Days 1-4</time_frame>
    <description>Maximum concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax</measure>
    <time_frame>Days 1-4</time_frame>
    <description>Time to maximum concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-infinity</measure>
    <time_frame>Days 1-4</time_frame>
    <description>Area under the plasma concentration-time curve (AUC) from time zero to infinity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess the incidence, frequency, and severity of treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>Approximately 45 days</time_frame>
    <description>Safety and tolerability of ZN-c5</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Treatment Sequence A-B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will take ZN-c5 (150mg), single dose, under fasted conditions, and a week later, will take the same drug under fed conditions to determine the comparative bioavailability of ZN-c5 under these conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Sequence B-A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will take ZN-c5 (150mg), single dose, under fed conditions, and a week later, will take the same drug under fasted conditions to determine the comparative bioavailability of ZN-c5 under these conditions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZN-c5</intervention_name>
    <description>ZN-c5 is the study drug.</description>
    <arm_group_label>Treatment Sequence A-B</arm_group_label>
    <arm_group_label>Treatment Sequence B-A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy female volunteers&#xD;
&#xD;
          -  Body mass index (BMI) between &gt; or = 18.0 kg/m2 and &lt; or = 29.9 kg/m2, and a body&#xD;
             weight &gt; or = 50kg and &lt; or = 100kg at Screening&#xD;
&#xD;
          -  Non-smoker and must not have used any tobacco products within 2 months prior to&#xD;
             Screening, or if a smoker must be currently (and for the last 2 months prior to&#xD;
             screening) smoking &lt; or = 2 cigarettes or equivalent per week. Current smokers must be&#xD;
             willing to abstain from the use of tobacco and products containing nicotine from 14&#xD;
             days prior to administration of study drug and through the EOS visit.&#xD;
&#xD;
          -  No relevant dietary restrictions, and be willing to consume a high calorie, high fat&#xD;
             breakfast and other standard meals provided during the domiciled periods of the study&#xD;
&#xD;
          -  Post-menopausal for &gt; or = 24 months. Status will be confirmed through testing of&#xD;
             follicle-stimulating hormone (FSH) levels &gt; or = 40 IU/L at Screening. Participants&#xD;
             that are post-menopausal for &lt; or = 24 months are still potentially eligible, but will&#xD;
             be required to have a negative serum pregnancy test result at Screening and negative&#xD;
             urine pregnancy test result prior to study drug administration.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any condition likely to affect the participant's ability to consume the standard meal&#xD;
             provided during the domiciled periods of the study, or any condition that may make it&#xD;
             difficult for the patient to comply with the requirement for fasting during the study&#xD;
&#xD;
          -  Blood donation or significant blood loss within 60 days prior to the first study drug&#xD;
             administration&#xD;
&#xD;
          -  Plasma donation within 7 days prior to the first study drug administration&#xD;
&#xD;
          -  Fever (body temperature &gt; or = 38C) or symptomatic viral or bacterial infection or&#xD;
             febrile illness within 2 weeks prior to Screening&#xD;
&#xD;
          -  Positive serum pregnancy test at Screening or urine pregnancy test prior to&#xD;
             administration of study drug (for participants who are post-menopausal for &lt; or = 24&#xD;
             months only)&#xD;
&#xD;
          -  Positive toxicology screening panel or alcohol breath test&#xD;
&#xD;
          -  History of substance abuse or dependency or history of recreational intravenous (IV)&#xD;
             drug use over the last 5 years (by self-declaration)&#xD;
&#xD;
          -  Regular alcohol consumption within the 6 months prior to study drug administration,&#xD;
             defined as &gt; 21 alcohol units per week&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dimitris Voliotis</last_name>
    <role>Study Chair</role>
    <affiliation>Zeno Alpha Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site 1</name>
      <address>
        <city>Christchurch</city>
        <zip>8011</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>September 18, 2020</study_first_submitted>
  <study_first_submitted_qc>September 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2020</study_first_posted>
  <last_update_submitted>December 22, 2020</last_update_submitted>
  <last_update_submitted_qc>December 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Randomized</keyword>
  <keyword>Postmenopause</keyword>
  <keyword>Female</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

